Actively Recruiting
Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome
Led by University Hospital, Bonn · Updated on 2022-05-18
1000
Participants Needed
1
Research Sites
495 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluation of non-invasive prognostic parameters in patients developing ACLF and renal failure in patients receiving and not receiving transjugular intrahepatic portosystemic shunt (TIPS). Patients are cared according to the local standardized follow up program. Clinical and laboratory data from standard patient care are evaluated for potential prognostic value.
CONDITIONS
Official Title
Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All patients with portal hypertension and kidney failure
You will not qualify if you...
- No consent
- No kidney failure
- No portal hypertension
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Bonn
Bonn, Germany
Actively Recruiting
Research Team
M
Michael Praktiknjo, MD
CONTACT
J
Johannes Chang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here